UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE and CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Overview

CHRONIC OBSTRUCTIVE PULMONARY DISEASE is the #8 most commonly reported adverse reaction for UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, manufactured by GlaxoSmithKline LLC. There are 607 FDA adverse event reports linking UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE to CHRONIC OBSTRUCTIVE PULMONARY DISEASE. This represents approximately 2.0% of all 30,147 adverse event reports for this drug.

Patients taking UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE who experience chronic obstructive pulmonary disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

CHRONIC OBSTRUCTIVE PULMONARY DISEASE is a less commonly reported adverse event for UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, but still significant enough to appear in the safety profile.

Other Side Effects of UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

In addition to chronic obstructive pulmonary disease, the following adverse reactions have been reported for UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE:

• DYSPNOEA — 2,306 reports
• DRUG INEFFECTIVE — 1,589 reports
• WRONG TECHNIQUE IN DEVICE USAGE PROCESS — 1,571 reports
• PRODUCT COMPLAINT — 1,130 reports
• COUGH — 1,073 reports
• PRODUCT DOSE OMISSION ISSUE — 835 reports
• PNEUMONIA — 651 reports
• CONDITION AGGRAVATED — 498 reports
• DRUG DISPENSING ERROR — 496 reports
• DRUG DOSE OMISSION — 472 reports

Other Drugs Associated with CHRONIC OBSTRUCTIVE PULMONARY DISEASE

The following drugs have also been linked to chronic obstructive pulmonary disease in FDA adverse event reports:

Does UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE cause CHRONIC OBSTRUCTIVE PULMONARY DISEASE?

CHRONIC OBSTRUCTIVE PULMONARY DISEASE has been reported as an adverse event in 607 FDA reports for UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is CHRONIC OBSTRUCTIVE PULMONARY DISEASE with UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE?

CHRONIC OBSTRUCTIVE PULMONARY DISEASE accounts for approximately 2.0% of all adverse event reports for UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, making it a notable side effect.

What should I do if I experience CHRONIC OBSTRUCTIVE PULMONARY DISEASE while taking UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE?

If you experience chronic obstructive pulmonary disease while taking UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages